行情

PIRS

PIRS

Pieris Pharms
NASDAQ

实时行情|Nasdaq Last Sale

3.870
+0.030
+0.78%
盘后: 3.870 0 0.00% 16:00 11/15 EST
开盘
3.900
昨收
3.840
最高
3.950
最低
3.810
成交量
41.47万
成交额
--
52周最高
6.04
52周最低
2.390
市值
1.91亿
市盈率(TTM)
-5.0143
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PIRS 新闻

  • 分析师:某位投资大佬可能正在“嗅探”Netflix
  • 新浪财经.1小时前
  • FAA局长:737 MAX机型获复飞批准"不受时间表指引"
  • 新浪美股.1小时前
  • ExodusPoint对冲基金将重新开放 拟募集超过20亿美元
  • 新浪美股.2小时前
  • 愿景基金二期已筹集20亿美元 但尚不及目标资金零头
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+1.49%
制药与医学研究
+1.29%

热门股票

名称
价格
涨跌幅

PIRS 简况

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
展开

Webull提供Pieris Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。